Trial Watch: Edition 12

Trial Watch Edition 12 captures high signal clinical development activity from June 16 to June 30, 2026.

This edition is defined by four major shifts across oncology, cardiometabolic medicine, neurology and advanced modalities. Roche is entering obesity at scale through parallel Enicepatide and Petrelintide programs, while Boehringer Ingelheim adds another obesity signal with BI 3034701.

In oncology, BCMA bispecific competition in first line multiple myeloma continues to intensify, while CLDN18.2, TROP2 ADCs, KRAS G12C and Factor XI inhibition all move through strategically important trial designs.

At the same time, advanced modalities are expanding through AAV gene therapy, retinal gene therapy and universal CAR T in recurrent glioblastoma, showing how platform technologies are moving into increasingly complex disease areas.